AstraZeneca Announces C$820 Million Investment for Global Expansion and Innovation
Friday, January 24, 2025
AstraZeneca has announced plans to invest C$820 million (US$570 million) in Canada.
The initiative is expected to create over 700 high-skilled jobs across various areas of its business and will include the development of a new, state-of-the-art office facility in the Greater Toronto Area, Ontario.
This investment aligns with AstraZeneca’s global goal of reaching US$80 billion in total revenue and introducing 20 new medicines by 2030. To date, eight medicines have already been delivered, with data from seven Phase III clinical trials anticipated in 2025.
In 2023, AstraZeneca invested over C$230 million in research and development in Canada, contributing significantly to its global clinical studies. The company is currently conducting more than 210 clinical trials to evaluate new medicines and indications.
Since 2023, AstraZeneca’s investments in Canada have exceeded C$1.3 billion, resulting in the creation of 1,200 high-skilled jobs.
In 2024, AstraZeneca acquired Hamilton-based Fusion Pharmaceuticals for C$3 billion. This acquisition supports the development of next-generation radioconjugates designed to revolutionise cancer radiotherapy.
It stands as one of the largest research investments in a Canadian biotechnology firm. These initiatives collectively strengthen Canada’s life sciences sector and support AstraZeneca’s expanding global clinical studies.
Ontario’s government, through Invest Ontario, has supported AstraZeneca’s efforts with funding of C$16.1 million.
AstraZeneca’s commitment reflects confidence in Canada’s potential as a global hub for life sciences, leveraging the country’s skilled workforce, academic institutions, hospitals, and research centres to advance medical innovation for patients in Canada and beyond.
This partnership aims to enhance Ontario’s life sciences strategy, drive innovation, and support the development of treatments for diseases such as prostate, lung, and breast cancers, as well as rare conditions.
Source: astrazeneca.com
